Trial Profile
Noradrenergic Augmentation of SSRI [selective serotonin reuptake inhibitor] therapy in patients with depression unresponsive or incompletely responsive to SSRI monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Sertraline (Primary)
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Jan 2010 Results were published in Psychiatry Research.
- 18 Jun 2007 New trial record.